PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
|Articles|January 2, 2021
- Pharmaceutical Technology-01-02-2021
- Volume 45
- Issue 1
Sanitary Ribbon Blenders
ROSS’ Sanitary Ribbon Blenders with ergonomic material handling accessories feature a new design that allows operators to safely empty bags of powder through a bar grating while an adjacent vibrating tray assembly catches debris and off-spec ingredients.
ROSS’ Sanitary Ribbon Blenders with ergonomic material handling accessories feature a new design that allows operators to safely empty bags of powder through a bar grating while an adjacent vibrating tray assembly catches debris and off-spec ingredients. Now available on all Ribbon Blenders, including the Model 42N-18SS (pictured), the new design uses safety limit switches to prevent operation of the agitator if access ports are open or if the grating is removed.
Additionally, the blenders come equipped with a sanitary 4-inch spherical disc discharge valve with a pneumatic actuator and UL-listed operator controls in a NEMA 4X stainless steel enclosure with 3R fan shrouds, variable frequency drive, digital speed and amperage readouts, dial-type potentiometer, cycle timer, and E-Stop. All interior and exterior surfaces of the blenders are stainless steel, polished to 150-grit sanitary finish.
Articles in this issue
over 5 years ago
Bringing Bio/Pharma’s “New Normal” Into Focusover 5 years ago
The Outlook for a Year of Changeover 5 years ago
Compensation Does Not Necessarily Align With Job Satisfactionover 5 years ago
Talent-Driven Market for Laboratory Techniciansover 5 years ago
ECHA’s Microplastics Use Restriction—Impact on Pharmaceuticalsover 5 years ago
FDA Ends 2020 with High Drug Approval Rateover 5 years ago
Overcoming Biologic Drug Formulation Hurdlesover 5 years ago
Choosing a Cleanroom Infrastructure Technologyover 5 years ago
COVID-19 Vaccine Distribution: Preparing for the Unexpectedover 5 years ago
FDA Inspections Remain Stalled During the COVID-19 PandemicRelated to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
FDA's IND Pilot Puts CMC Review First
3
Mature Medicines Divestment Signals Shift in Manufacturing Strategy
4
Successful Internal Audit Planning and Execution
5